Drug intelligence / Profile preview

caspase-1 inhibitor (Elgia Therapeutics)

Development stage
Preclinical
Lead developer
Elgia Therapeutics
Modality
Small Molecules
01

Overview

Elgia Therapeutics' caspase-1 inhibitor is a preclinical small-molecule drug candidate designed to treat chronic inflammatory and fibrotic diseases. It functions by selectively inhibiting caspase-1, a cysteine protease that plays a critical role in the NLRP3 inflammasome pathway. By blocking caspase-1 activity, the drug prevents the proteolytic cleavage and activation of pro-inflammatory cytokines, specifically interleukin-1 beta (IL-1β) and interleukin-18 (IL-18), thereby suppressing downstream inflammatory cascades. The program is currently being evaluated for the treatment of cryopyrin-associated periodic syndrome (CAPS) and inflammatory bowel disease (IBD), including colitis.

Other names
Elgia caspase-1 inhibitor
02

Targets

CASP1 (Caspase-1)

Beyond the preview

Go deeper on caspase-1 inhibitor (Elgia Therapeutics).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on caspase-1 inhibitor (Elgia Therapeutics).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call